

Top 50 companies by R&D projects league table – July 2009

The table below summarizes the top 50 companies in Pharmaprojects, the leading database tracking pharmaceutical development from early preclinical study through to launch or discontinuation, in July 2009. It lists companies in descending order by total number of active research and development (R&D) projects (excluding suspended products). Each company's total R&D products are separated into the number of drugs originating from its own research and the number of drugs it has licensed-in. The table also shows subtotals at 10 place intervals. The percentage values represent the number of drugs in R&D as a proportion of the total number of R&D projects listed in Pharmaprojects in July 2009.

Position July 2009	No of R&D drugs	No of own drugs	No under licence	
1	GlaxoSmithKline *	249	157	92
2	Hoffmann-La Roche *	191	123	68
3	Merck & Co *	173	115	58
4	AstraZeneca *	169	123	46
5	Novartis *	165	99	66
6	Pfizer *	163	117	46
7	Sanofi-Aventis *	160	103	57
8	Johnson & Johnson	141	83	58
9	Eli Lilly *	131	98	33
10	Wyeth	100	75	25
Subtotal: top 10		1642 (16.7%)	1093 (11%)	549 (20%)
11	Takeda	95	50	45
12	Schering-Plough	86	40	46
13	Bayer *	84	56	28
14	Bristol-Myers Squibb *	84	60	24
15	Abbott *	82	65	17
16	Astellas	73	44	29
17	Daiichi Sankyo	72	45	27
18	Eisai	61	39	22
19	Kyowa Hakko Kirin	60	34	26
20	Merck KGaA *	57	19	38
Subtotal: top 20		2396 (24.5%)	1545 (15.6%)	851 (30.9%)
21	Amgen	56	40	16
22	Boehringer Ingelheim *	54	38	16
23	Shionogi	50	26	24
24	Mitsubishi Tanabe Pharma	47	32	15
25	Solvay *	46	28	18
26	Biogen Idec	41	20	21
27	Genzyme	41	29	12
28	Ipsen	41	27	14
29	Isis Pharmaceuticals	40	29	11
30	Novo Nordisk *	40	30	10
Subtotal: top 30		2852 (29.2%)	1844 (18.7%)	1008 (36.7%)
31	Shire	40	20	20
32	Cancer Research Technology	39	32	7
33	Gilead Sciences	39	31	8
34	Cephalon	34	24	10
35	Allergan	34	21	13
36	Inovio	33	25	8
37	Medarex	33	24	9
38	HanAll Pharmaceutical	32	32	0
39	Baxter International	30	16	14
40	Immunomedics	30	30	0
Subtotal: top 40		3196 (32.6%)	2099 (21.2%)	1097 (40%)
41	LG Life Sciences	30	21	9
42	Ligand	30	21	9
43	Elan	29	14	15
44	Dainippon Sumitomo Pharma	28	21	7
45	CSL *	27	14	13
46	Green Cross	27	20	7
47	UCB *	27	18	9
48	Dong-A	26	19	7
49	Daewoong	26	16	10
50	Alnylam	26	26	0
Subtotal: top 50		3472 (35.5%)	2289 (23.1%)	1183 (43.2%)

*P-D-R member company

For further information: <http://www.pharmaprojects.com>. Copyright Informa UK Ltd 2009. All rights reserved.